サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519762

抗脂質異常症薬市場レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、2024年～2032年

Antihyperlipidemic Drugs Market Report by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 136 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
抗脂質異常症薬市場レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗脂質異常症薬の市場規模は2023年に126億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに182億米ドルに達し、2024年から2032年の間に4.1%の成長率（CAGR）を示すと予測しています。

抗脂質異常症薬は、血中のコレステロールや様々な脂質の血清レベルを下げるのに役立ちます。抗脂質異常症薬は、高コレステロールをコントロールし、特定の病状のリスクを軽減するために、さまざまな薬と併用することができます。現在、世界中で様々なクラスの抗脂質異常症薬が販売されており、患者のコレステロール値、基礎疾患、その他の要因に基づいて投与することができます。一般的に使用可能な抗脂質異常症薬には、スタチン、抗脂質異常症薬の配合剤、胆汁酸分泌抑制薬、コレステロール吸収阻害薬、フィブリン酸誘導体、PCSK9阻害薬などがあります。

抗脂質異常症薬市場動向：

座りがちなライフスタイル、ニコチン中毒、脂肪分の多い食品の大量摂取を原因とする高脂血症の有病率の増加は、抗脂質異常症薬の需要を喚起する重要な要因の一つです。さらに、高脂血症は冠動脈疾患（CAD）の発症リスクを高める。その結果、低比重リポ蛋白（LDL）コレステロールとトリグリセリドの高値を下げる一方、高比重リポ蛋白（HDL）コレステロールの低値を上げる薬剤の必要性が高まっています。これとは別に、コレステロール値が高い子供や様々な脂質異常症の治療にも使用されています。加えて、小児集団における脂質およびリポ蛋白代謝の遺伝的・後天的障害の急増は、入院や早死を減らすための抗脂質異常症薬の必要性にプラスの影響を与えています。さらに、新薬や先端薬の承認が市場に有利な見通しをもたらしています。これに加えて、世界中の医薬化学者がこれらの薬剤のために様々な新しい分子を設計、合成、評価しており、市場の成長に寄与すると予想されます。

本レポートで扱う主な質問

  • 2023年の世界の抗脂質異常症薬市場の市場規模は？
  • 2024～2032年の世界の抗脂質異常症薬市場の予想成長率は？
  • 世界の抗脂質異常症薬市場を牽引する主な要因は？
  • 世界の抗脂質異常症薬市場に対するCOVID-19の影響は？
  • 世界の抗脂質異常症薬市場の薬剤クラス別内訳は？
  • 世界の抗脂質異常症薬市場の主要地域は？
  • 世界の抗脂質異常症薬市場の主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の抗脂質異常症薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • スタチン
    • 市場動向
    • 市場予測
  • 胆汁酸吸着剤
    • 市場動向
    • 市場予測
  • コレステロール吸収阻害剤
    • 市場動向
    • 市場予測
  • フィブリン酸誘導体
    • 市場動向
    • 市場予測
  • PCSK9阻害剤
    • 市場動向
    • 市場予測
  • 組み合わせ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 静脈内
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売店
    • 市場動向
    • 市場予測
  • オンライン小売業者
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
図表

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players
目次
Product Code: SR112024A5622

The global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

PCSK9 Inhibitors

Combination

Others

Breakup by Route of Administration:

Oral

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Stores

Online Retailers

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global antihyperlipidemic drugs market in 2023?
  • 2. What is the expected growth rate of the global antihyperlipidemic drugs market during 2024-2032?
  • 3. What are the key factors driving the global antihyperlipidemic drugs market?
  • 4. What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
  • 5. What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
  • 6. What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
  • 7. What are the key regions in the global antihyperlipidemic drugs market?
  • 8. Who are the key players/companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials